医薬品・バイオテクノロジー業界の資産購入契約 (2019-2025年)

本レポートでは、2019年から2025年までの医薬品業界の資産購入契約の詳細を提供し、企業がどのように、なぜ事業・製品・技術・ロイヤルティ資産の買収契約を締結するのかについて、詳細な理解と分析を提供します。当事者間で発表された資産購入契約の支払い条件へのアクセスを提供し、支払い条件やその他の取引条件について有益な洞察を提供します。

本レポートでは、主要な4タイプの資産に焦点を当てています：

• 事業資産
• 製品資産
• ロイヤルティ資産
• 技術資産

主な利点

本レポートは、読者に以下の主な利点を提供します：

• 2019年以降の契約動向への理解
• 資産購入契約の閲覧
• ベンチマーク分析：取引の市場価値の把握
• 財務条件：契約総額、一時金、マイルストーン、ロイヤルティ率
• 契約ディレクトリ：企業別 (A～Z)、治療分野別、技術タイプ別
• 主要契約：金額別
• 最も活発な契約締結企業の特定
• 各取引の資産および契約条件の特定
• 契約文書へのアクセス：契約構造に関する洞察
• デューデリジェンス：提携企業に対する自社の契約条件の適合性の評価
• 数百時間の調査時間を節約可能

調査範囲

• ライフサイエンス業界における資産購入契約の動向
• 資産購入契約構造の概要
• 製薬、バイオテクノロジー、医療機器、診断分野を対象とした資産購入契約記録のディレクトリ
• 契約金額が大きい主要な資産購入契約
• 最も活発に資産購入契約を行っている企業
• 主要な資産購入提携リソース

利用可能な契約のリスト：

• 企業 (A～Z)
• 契約総額
• 治療分野
• 技術タイプ

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 資産購入取引の動向

• 資産購入契約の定義
• 2019年以降の資産購入契約の動向
  • 2019～2025年における資産購入契約：年別
  • 2019～2025年における資産購入契約：開発段階別
  • 2019～2025年における資産購入契約：業界別
  • 2019～2025年における資産購入契約：治療領域別
  • 2019～2025年における資産購入契約：技術タイプ別
  • 2019～2025年における資産購入契約：最も活発な企業別
• 資産購入提携契約を締結する理由
  • 事業資産
  • 製品資産
  • ロイヤルティ資産
  • 技術資産
• 資産購入契約の将来

第3章 資産購入契約の構造：概要

• 資産購入契約の構造

第4章 主要な資産購入契約

• トップ資産購入契約：金額別

第5章 最も活発な資産購入契約企業：トップ25社

• 最も活発な資産購入契約企業：トップ25社

第6章 契約ディレクトリを含む資産購入契約

• 2019年から2025年までの契約を含む資産購入契約
• 契約ディレクトリ
• 契約ディレクトリ- 企業別の資産購入契約 (A-Z)
• 契約ディレクトリ- 治療領域別の資産購入契約
• 契約ディレクトリ- 技術タイプ別の資産購入契約
• Biopharma Researchについて
• 現在の提携
• 現在の契約
• Current Partneringからの最近のレポートタイトル

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2019
  • 2.3.1. Asset purchase dealmaking by year, 2019-2025
  • 2.3.2. Asset purchase dealmaking by phase of development, 2019-2025
  • 2.3.3. Asset purchase dealmaking by industry sector, 2019-2025
  • 2.3.4. Asset purchase dealmaking by therapy area, 2019-2025
  • 2.3.5. Asset purchase dealmaking by technology type, 2019-2025
  • 2.3.6. Asset purchase dealmaking by most active company, 2019-2025
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2019-2025
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2019-2025
• Figure 3: Asset purchase deals signed at each phase of development, 2019-2025
• Figure 4: Asset purchase deals by industry sector, 2019-2025
• Figure 5: Asset purchase deals by therapy area, 2019-2025
• Figure 6: Asset purchase deals by technology type, 2019-2025
• Figure 7: Top 25 most active asset purchase dealmakers, 2019-2025
• Figure 8: Top asset purchase deals by value, 2019-2025
• Figure 9: Most active asset purchase dealmakers, 2019-2025